• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

16.78 -0.84 (-4.77%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 819,997
Open 17.60
Bid (Size) 14.00 (100)
Ask (Size) 27.13 (200)
Prev. Close 17.62
Today's Range 16.69 - 17.78
52wk Range 13.70 - 30.99
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 05, 2026
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 03, 2026
From Bicara Therapeutics Inc.
Via GlobeNewswire

Performance

52-Week Range 45.9% below 52-week high
16.78
13.7052W Low 30.9952W High
1 Week 6.7% below 1-week high
16.881W Low 17.991W High

Bicara Therapeutics Inc. - Common Stock (BCAX) traded between $13.70 and $30.99 over the past 52 weeks and last traded at $16.78, 45.9% below its 52-week high. Over the past week it ranged between $16.88 and $17.99.

Past 12 Months
-4.1%
-26.0%
-39.2%
-29.9%
+2.4%
-10.8%
1W -$0.72
1M -$5.89
3M -$10.82
6M -$7.15
YTD +$0.40
1Y -$2.03

BCAX was -10.8% over the past year, -29.9% over six months, +2.4% year to date, -4.1% in the last week.

12 Months vs Market
BCAX
-10.8%
DIA
+12.2%
SPY
+14.7%
QQQ
+17.9%
IWM
+8.0%

Over the past 12 months BCAX returned -10.8% versus DIA (Dow) +12.2%, SPY (S&P 500) +14.7%, QQQ (Nasdaq 100) +17.9% and IWM (Russell 2000) +8.0%.

Volume & Liquidity 1.25× 3-mo avg
Today 819,997 3-mo avg 656.4K
1W
946.6K
1M
831.6K
3M
656.4K
6M
668.2K
YTD
622.5K
1Y
640.9K

BCAX most recently traded 819,997 shares against a 3-month average daily volume of 656.4K.

More News

Read More
News headline image
Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript ↗
August 18, 2026
Via The Motley Fool
Topics Earnings
News headline image
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
August 14, 2026
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics (NASDAQ:BCAX) Q1 2026 Results Highlight Clinical Progress as EPS Misses Estimates ↗
May 11, 2026
Via Chartmill
News headline image
Bicara Therapeutics Q2 Earnings Call Highlights ↗
August 11, 2026
Via MarketBeat
Topics Earnings
News headline image
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth
August 11, 2026
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
August 04, 2026
From Bicara Therapeutics Inc.
Via GlobeNewswire
Top movers in Friday's after hours session ↗
July 31, 2026
Via Chartmill
News headline image
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
July 28, 2026
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? ↗
June 13, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara (BCAX) Q4 2025 Earnings Transcript ↗
June 01, 2026
Via The Motley Fool
News headline image
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer ↗
May 22, 2026
Via MarketBeat
News headline image
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
May 21, 2026
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet ↗
May 15, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back ↗
May 15, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data ↗
May 14, 2026
Via MarketBeat
News headline image
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
May 13, 2026
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara (BCAX) Q1 2026 Earnings Transcript ↗
May 11, 2026
Via The Motley Fool
News headline image
Bicara Therapeutics Q1 Earnings Call Highlights ↗
May 11, 2026
Via MarketBeat
Topics Earnings
News headline image
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 11, 2026
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000 ↗
May 04, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
May 04, 2026
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
April 03, 2026
From Bicara Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Bicara Therapeutics Inc. - Common Stock publicly traded?
Yes, Bicara Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Bicara Therapeutics Inc. - Common Stock trade on?
Bicara Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Bicara Therapeutics Inc. - Common Stock?
The ticker symbol for Bicara Therapeutics Inc. - Common Stock is BCAX on the Nasdaq Stock Market
What is the current price of Bicara Therapeutics Inc. - Common Stock?
The current price of Bicara Therapeutics Inc. - Common Stock is 16.78
When was Bicara Therapeutics Inc. - Common Stock last traded?
The last trade of Bicara Therapeutics Inc. - Common Stock was at 10/16/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap